Current filters:

RituxanBiogen Idec

1 to 9 of 95 results

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan


The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus


Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch


US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

Roche gets US FDA approval for Rituxan for follicular lymphoma maintenance; Tarceva meets primary endpoint


Swiss drug major Roche’s (ROG: VX) subsidiary Genentech and Biogen Idec (Nasdaq: BIIB) on Friday…

Biogen IdecBiotechnologyGenentechNorth AmericaOncologyPharmaceuticalRegulationResearchRituxanRocheTarceva

Genentech and Biogen sue GlaxoSmithKline and Genmab over Arzerra patent


US biotechnology giant Genentech, a wholly-owned subsidiary of Switzerland’s Roche, and Biogen Idec…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineOncologyPatentsPharmaceuticalRituxanRoche

Biogen Idec 2009 results beat forecasts, boosted by Tysabri sales growth


US biotechnology firm Biogen Idec reported total revenues for full-year 2009 of $4.4 billion, an increase…

AvonexBiogen IdecBiotechnologyFinancialInterferon beta-1aNatalizumabPharmaceuticalRebifRituxanrituximabTysabri

1 to 9 of 95 results

Back to top